Photo from Paolo Tarantino/Twitter
Jul 28, 2023, 08:26
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? – Paolo Tarantino
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support?
Which one should be utilized first? Find the answer in our latest letter to the editor, now published on Annals of Oncology, Giuseppe Curigliano, Sara Tolaney.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2024, 06:23